RUI 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity

Journal of Steroid Biochemistry and Molecular Biology

Volumn 59, Issue 5-6, 1996, Pages 449-457

  Van De Velde, P ^a   Nique, F ^a   Planchon, P ^b   Prevost G ^b,c   Bremaud J ^a   Hameau, M C ^a   Magnien, V ^b   Philibert, D ^a   Teutsch, G ^a  

^a SANOFI   (France)

^b IOCMH   (France)

^c Institut Henri Beaufour   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; DOXORUBICIN; ESTRADIOL; FULVESTRANT; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CULTURE; CELL CYCLE; CELL LINE; CELL STRAIN MCF 7; CHICK EMBRYO; CONTROLLED STUDY; FEMALE; HEART; HISTOLOGY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER INVASION; CARCINOGEN TESTING; CELL DIVISION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; HEART MUSCLE; KINETICS; METASTASIS; METHODOLOGY; NUDE MOUSE; ONCOGENE RAS; PATHOLOGY; PRENATAL DEVELOPMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOGENICITY TESTS; CELL CYCLE; CELL DIVISION; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENES, RAS; HEART; HUMANS; KINETICS; MICE; MICE, INBRED BALB C; MICE, NUDE; MYOCARDIUM; NEOPLASM INVASIVENESS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0030300130     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(96)00140-9     Document Type: Article

References (25)

1. 1. Stahl M., Wilke H., Schmoll H. J., Schober C., Diedrich H., Casper J., Freund M. and Polidova H.: A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann. Oncol. 3 (1992) 167-168.
2. 2. Tang B. L., Teo C. C., Sim K. J., Ng M. L. and Kon O. N.: Cytostatic effect of antiestrogens in lymphoid cells: relationship to high affinity antiestrogen-binding sites and cholesterol. Biochim. Biophys. Acta 1014 (1989) 162-172.
3. 3. Rumke P., Kleeberg U. R., MacKie R. M., Lejeune F. J., Planting A. S., Brocker E. B., Bierhorst J. F. and Lentz M. A.: Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC malignant melanoma cooperative group. Melanoma Res. 2 (1992) 153-156.
4. 4. Vertosick F. t. Jr, Selker R. J., Pollack I. F. and Arena V.: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery 30 (1992) 897-903.
5. 5. Farinati F., De Maria N., Fornesiaro A., Salvagnini M., Fagiuoli S., Chiaramonte M. and Naccarato R.: Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig. Dis. Sci. 37 (1992) 659-662.
6. 6. Panettiere F. J., Groppe C. W., Athens J. W., Costanzi J. J., Bonnet J. D., Saiki J. H. and Chen T. T.: Tamoxifen therapy and colorectal adenocarcinoma: a southwest oncology group study. Cancer Treat. Rep. 69 (1985) 113-114.
7. 7. Wong A., Chan A. and Arthur K.: Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat. Rep. 71 (1987) 749-750.
8. 8. Jordan V. C.: The only true antiestrogen is no estrogen. Molec. Cell. Endocr. 74 (1990) C91-C95.
9. 9. Fornander T., Cedermark B., Mattsson A., Skoog L., Theve T., Askergren J., Rutqvist L. E., Glas U., Silfverswärd C., Somell A., Wilking N. and Hjarlmar M.-L.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 8630 (1989) 117-119.
10. 10. Gottardis M. M. and Jordan V. C.: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48 (1988) 5183-5187.
11. 11. Legault-Poisson S., Jolivet J., Poisson R., Beretta-Piccoli M. Band P. R.: Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep. 63 (1979) 1839-1841.
12. 12. Cullen K. J., Smith H. S., Hill S., Rosen N. and Lippman M. E.: Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res. 51 (1991) 4978-4985.
13. 13. Dickson B. D., McManaway M. E. and Lippman M. E.: Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 232 (1986) 1540-1542.
14. 14. Wakeling A. E., Dukes M. and Bowler J.: A potent specific pure antiestrogen with clinical potential. Cancer Res. 51 (1991) 3867-3873.
15. 15. Van de Velde P., Nique F., Bouchoux F., Brémaud J., Hameau M.-C., Lucas D., Moratille C., Viet S., Philibert D. Teutsch G.: RU 58668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J. Steroid Biochem. Molec. Biol. 48 (1994) 187-196.
16. 16. Colletti R. B., Roberts J. D., Devlin J. T. and Copeland K. C.: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 49 (1989) 1882-1884.
17. 17. Wakeling A. E. and Bowler J.: Novel antioestrogens without partial agonist activity. J. Steroid. Biochem. 31 (1988) 645-653.
18. 18. Wakeling A. E.: Therapeutic potential of pure antiestrogens in the treatment of breast cancer. J. Steroid Biochem. Molec. Biol. 37 (1990) 771-775.
19. 19. De Friend D. J., Howell A., Nicholson R. I., Anderson E., Dowsett M., Mansel R. E., Blamey R. W., Bundred N. J., Robertson J. F., Saunders C., Baum M., Walton P., Sutcliffe F. and Wakeling A. E.: Investigation of a new pure antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res. 54 (1994) 408-414.
20. 20. Howell A., Defriend D. J., Blamey R. W., Robertson J. F. and Walton P. J.: Investigation of a pure antioestrogen (ICI 182,780) in tamoxifen resistant breast cancer. Eur. J. Cancer 30A (1994) S24.
21. 21. Van de Velde P., Nique F., Brémaud J., Hameau M.-C., Philibert D. and Teutsch G.: Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment. Ann. NY Acad. Sci. 761 (1995) 164-175.
22. 22. Van de Velde P., Nique F., Brémaud J., Delettre G., Hameau M. C., Lucas D., Moratille C., Philibert D. and Teutsch G.: RU 58668: Profil des activités pharmacologiques d'un nouvel antiestrogène pur susceptible de traiter certains échappements au tamoxifène. Pathol. Biol. 42 (1994) 30.
23. 23. Nique F. and Van de Velde P.: RU 58668. Drugs Future 20 (1995) 362-366.
24. 24. Khochbin S., Chabanas A., Albert P., Albert J. and Laurence J. J.: Application of bromodeoxyuridine incorporation measurements to the determination of cell distribution within the S-phase of the cell cycle. Cytometry 9 (1988) 499-503.
25. 25. Sommers C. L., Papageorge A., Wilding G. and Gelmann P.: Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutant of ras. Cancer Res. 50 (1990) 67-71.